Treatment extends lives of patients with terminal ovarian and lung cancers

Patients in study had 'exhausted all other options' but new combination halted their cancer for an average of 5.8 months

A new treatment for patients with advanced ovarian and lung cancer could give them months longer to spend with their loved ones, early trial results suggest.

The combination of targeted drug vistusertib and paclitaxel chemotherapy stopped the growth of cancer for nearly six months and caused the tumours of some to shrink, according to the study published in Annals of Oncology.